|Bid||33.090 x 10200|
|Ask||33.100 x 8400|
|Day's Range||33.060 - 33.450|
|52 Week Range||29.830 - 35.380|
|PE Ratio (TTM)||27.86|
|Dividend & Yield||1.28 (3.84%)|
|1y Target Est||N/A|
The U.S. Food and Drug Administration (FDA) said on Thursday it approved Pfizer Inc's rare blood cancer drug, Besponsa, with a boxed warning. A boxed warning is the agency's severest form of warning reserved to caution against the most serious side effects. Besponsa was approved to treat adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL), a disease that will affect about 5,970 people in the United States this year and kill about 1,440, according to the National Cancer Institute.
Pfizer, Inc.'s (PFE) newly approved anti-PD-L1 immunotherapy, Bavencio, is being touted as a significant top-line driver for this New York-based pharma giant.
In 2Q17, Amgen’s (AMGN) Aranesp generated revenues of ~$535 million, which represented a 6% year-over-year rise.